Ken Griffin Capricor Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 151,900 shares of CAPR stock, worth $2.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
151,900
Previous 36,700
313.9%
Holding current value
$2.9 Million
Previous $175,000
1220.0%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding CAPR
# of Institutions
92Shares Held
8.13MCall Options Held
1.78MPut Options Held
1.4M-
Black Rock Inc. New York, NY1.63MShares$31.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.58MShares$30.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA638KShares$12.2 Million0.0% of portfolio
-
State Street Corp Boston, MA512KShares$9.78 Million0.0% of portfolio
-
Superstring Capital Management LP New York, NY337KShares$6.44 Million4.49% of portfolio
About CAPRICOR THERAPEUTICS, INC.
- Ticker CAPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,346,200
- Market Cap $465M
- Description
- Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...